Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Name: Αlpha¹ Rigor Record — Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Item: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Rating: 100
Author: Αlpha¹

Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4.5★ (Strong), 0 critical, 0 high issues for “Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4.5 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Problems surfaced2 types

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted, transparently reported phase 3 randomized trial update. All eight rigor dimensions are adequately addressed, with minor reporting gaps (e.g., no explicit CONSORT statement, no exact p-values, no power analysis for the update) that do not undermine the core findings. The main caveats are the open-label design and the small number of male patients, both acknowledged in the paper.

Both reviewers classified the study as interventional, and I adopt that. The evaluation covered the full text, with all eight dimensions applicable. The statistics verification component checked 0 tests (none recomputable), so statistical correctness is not independently confirmed beyond the reported methods. The integrity check flagged retrospective registration of the phase 1b trial (NCT02564900), which is a transparency concern but does not affect the current trial's reporting.

6 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior studies (phase 1b, primary DESTINY-Breast04 results, ASCO/CAP guidelines) and explains the biological rationale for HER2-low as a targetable category. It acknowledges limitations such as challenges in HER2-low identification and the exploratory nature of subgroup analyses. The hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on HER2-low breast cancer and the rationale for T-DXd, and it addresses limitations of prior work.

Evidence

paraphrase[Introduction, paragraph 3]

“The DESTINY-Breast04 primary analysis (data cutoff 11 January 2022) showed that T-DXd significantly improved progression-free survival (PFS) by blinded independent central review (BICR), the primary endpoint (in the HR+ cohort), and OS compared with TPC.”

direct quote[Introduction, last paragraph]

“Here we report a preplanned updated OS analysis, long-term safety and exploratory analyses of HR−, ER-low-positive and ER IHC >10% subgroups from DESTINY-Breast04 after longer follow-up (data cutoff 1 March 2023).”